title: Urine metabolomics analysis for biomarker discovery and detection of jaundice syndrome in patients with liver disease.
abstract: Metabolomics is a powerful new technology that allows for the assessment of global metabolic profiles in easily accessible biofluids and biomarker discovery in order to distinguish between diseased and nondiseased status information. Deciphering the molecular networks that distinguish diseases may lead to the identification of critical biomarkers for disease aggressiveness. However, current diagnostic methods cannot predict typical Jaundice syndrome (JS) in patients with liver disease and little is known about the global metabolomic alterations that characterize JS progression. Emerging metabolomics provides a powerful platform for discovering novel biomarkers and biochemical pathways to improve diagnostic, prognostication, and therapy. Therefore, the aim of this study is to find the potential biomarkers from JS disease by using a nontarget metabolomics method, and test their usefulness in human JS diagnosis. Multivariate data analysis methods were utilized to identify the potential biomarkers. Interestingly, 44 marker metabolites contributing to the complete separation of JS from matched healthy controls were identified. Metabolic pathways (Impact-value≥0.10) including alanine, aspartate, and glutamate metabolism and synthesis and degradation of ketone bodies were found to be disturbed in JS patients. This study demonstrates the possibilities of metabolomics as a diagnostic tool in diseases and provides new insight into pathophysiologic mechanisms.
authors.affiliation: National TCM Key Lab of Serum Pharmacochemistry, Heilongjiang University of Chinese Medicine, Key Pharmacometabolomics Platform of Chinese Medicines, Heping Road 24, Harbin 150040, China. xijunwangls@126.com
authors.forename: Xijun
authors.initials: X
authors.lastname: Wang
authors.forename: Aihua
authors.initials: A
authors.lastname: Zhang
authors.forename: Ying
authors.initials: Y
authors.lastname: Han
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
authors.forename: Hui
authors.initials: H
authors.lastname: Sun
authors.forename: Gaochen
authors.initials: G
authors.lastname: Song
authors.forename: Tianwei
authors.initials: T
authors.lastname: Dong
authors.forename: Ye
authors.initials: Y
authors.lastname: Yuan
authors.forename: Xiaoxia
authors.initials: X
authors.lastname: Yuan
authors.forename: Miao
authors.initials: M
authors.lastname: Zhang
authors.forename: Ning
authors.initials: N
authors.lastname: Xie
authors.forename: He
authors.initials: H
authors.lastname: Zhang
authors.forename: Hui
authors.initials: H
authors.lastname: Dong
authors.forename: Wei
authors.initials: W
authors.lastname: Dong
mesh_terms: D000328:Adult; D000409:Alanine / Q000378:metabolism / Q000652:urine; D001224:Aspartic Acid / Q000378:metabolism / Q000652:urine; D015415:Biomarkers / Q000378:metabolism / Q000652:urine*; D002851:Chromatography, High Pressure Liquid; D018450:Disease Progression; D005260:Female; D018698:Glutamic Acid / Q000378:metabolism / Q000652:urine; D006801:Humans; D007565:Jaundice / Q000175:diagnosis / Q000378:metabolism / Q000652:urine*; D007657:Ketone Bodies / Q000378:metabolism / Q000652:urine; D008107:Liver Diseases / Q000378:metabolism / Q000652:urine*; D008297:Male; D013058:Mass Spectrometry; D053858:Metabolic Networks and Pathways; D055432:Metabolomics / Q000379:methods*; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
chemical_list: D015415:Biomarkers; D007657:Ketone Bodies; D001224:Aspartic Acid; D018698:Glutamic Acid; D000409:Alanine